Abstract
Ovarian cancer is the most lethal gynecological malignancy and the fifth cause of cancer mortality in women in the Western Countries. Advanced genomic analysis showed that most hereditary and a large proportion of sporadic ovarian cancers are associated with genetic and epigenetic aberrations either in BRCA1 and/or BRCA2 genes or in other genes involved in DNA repair and genomic stability. BRCA dysfunction identifies a major subset of ovarian cancers with peculiar epidemiological and clinical features, such as higher incidence in younger females, high-grade serous phenotype, better chemosensitivity and outcome. Being particularly sensitive to DNA-damaging agents, such as platinum compounds, these tumors are suitable for new therapeutic options that represent future challenges for oncologists. In this article we review the known molecular dysfunction in hereditary ovarian cancers and BRCAness and discuss the implications of new advances for more personalized treatments.
Highlights
Ovarian cancer (OC) is the leading cause of gynecological cancerrelated death and the fifth cause of cancer mortality in women in the Western Countries [1,2]
Hereditary breast cancer associated (BRCA)–mutated and BRCAness OCs have an improved overall survival compared to sporadic carcinomas [42]
The majority of data agree that the determinant is the higher sensitivity to double-strand breaks (DSBs) or to adducts generated by chemotherapeutic agents
Summary
Ovarian cancer (OC) is the leading cause of gynecological cancerrelated death and the fifth cause of cancer mortality in women in the Western Countries [1,2]. BRCA1- and BRCA2-mutated OCs are eligible, and tumor variants displaying BRCAness, if we consider that cells lacking other proteins involved in HR may become sensitive to PARP inhibitors [32,41].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
